Information Provided By: 
Fly News Breaks for November 7, 2019
DXCM
Nov 7, 2019 | 08:51 EDT
Raymond James analyst Jayson Bedford raised his price target for DexCom to $189 from $172 following the company's Q3 results. In a research note to investors, Bedford says that while there will always be competitive "noise," Dexcom remains one of the best growth stories in MedTech, supporting his Outperform rating.
News For DXCM From the Last 2 Days
DXCM
Apr 26, 2024 | 07:45 EDT
Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.
DXCM
Apr 25, 2024 | 17:21 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 25, 2024 | 16:05 EDT
DXCM
Apr 25, 2024 | 16:04 EDT
DXCM
Apr 25, 2024 | 15:11 EDT
Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.
DXCM
Apr 25, 2024 | 13:09 EDT
